Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.

Tamoxifen was granted FDA approval on 30 December 1977.

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

Phase 4
Completed
Conditions
Interventions
First Posted Date
2014-02-25
Last Posted Date
2017-07-02
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
56
Registration Number
NCT02070692
Locations
🇺🇸

Oregon Health & Science University (OHSU), Portland, Oregon, United States

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2014-02-13
Last Posted Date
2022-04-27
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
688
Registration Number
NCT02062489
Locations
🇨🇳

Guangdong Women and Children Hospital, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 14 locations

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

First Posted Date
2014-02-06
Last Posted Date
2024-08-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
198
Registration Number
NCT02057133
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States

🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 10 locations

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

First Posted Date
2013-07-11
Last Posted Date
2016-06-28
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
115
Registration Number
NCT01896050
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

Phase 3
Conditions
Interventions
First Posted Date
2013-01-01
Last Posted Date
2020-03-04
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
412
Registration Number
NCT01758146
Locations
🇮🇳

Department of Radiotherapy, Post Graduate Institute of Medical Education & Research, Chandigarh, India

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

First Posted Date
2012-07-11
Last Posted Date
2018-09-19
Lead Sponsor
German Breast Group
Target Recruit Count
56
Registration Number
NCT01638247
Locations
🇩🇪

Kliniken Essen-Mitte, Essen, Nordrhein-Westfalen, Germany

Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance

First Posted Date
2012-06-07
Last Posted Date
2018-08-01
Lead Sponsor
University of Utah
Target Recruit Count
52
Registration Number
NCT01614210
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2012-04-18
Last Posted Date
2023-06-28
Lead Sponsor
European Institute of Oncology
Target Recruit Count
1884
Registration Number
NCT01579734
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

A Study of LY2228820 in Participants With Advanced Cancer

First Posted Date
2011-07-14
Last Posted Date
2020-03-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
89
Registration Number
NCT01393990
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath